Advertisement
Australia markets closed
  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     
  • AUD/USD

    0.6446
    +0.0009 (+0.14%)
     
  • ASX 200

    7,642.10
    +36.50 (+0.48%)
     
  • OIL

    82.03
    -0.66 (-0.80%)
     
  • GOLD

    2,393.80
    +5.40 (+0.23%)
     
  • Bitcoin AUD

    95,429.82
    -3,190.30 (-3.23%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

TCMD, PT & ACB Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Tactile Systems Technology (NASDAQ: TCMD)
Class Period: May 7, 2018 - June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile’s medical devices was materially smaller; (2) to induce sales growth and share gains, Tactile and/or its employees were engaged in illicit and illegal sales and marketing activities in violation of applicable federal and state rules and public payer regulations; (3) the foregoing illicit and illegal sales and marketing activities increased the risk of a Medicare audit of Tactile’s claims and criminal and civil liability; (4) Tactile’s revenues were in part the product of unlawful conduct and thus unsustainable; and that as a result of the foregoing, (5) Defendants’ public statements, including its year-over-year revenue growth and the purported growth drivers, were materially false and misleading at all relevant times.

Pintec Technology Holdings Limited (NASDAQ: PT)
Class Period: Pintec securities aquired pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company’s October 2018 initial public offering ("IPO" or the "Offering")
Deadline: November 30, 2020
For more info: www.bgandg.com/pt
The Complaint alleges that the Registration Statement was false and misleading and omitted to state material facts, and specifically failed to disclose that: (1) the Company erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec’s internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, the Company’s financial results for fiscal 2017 and 2018 had been misstated; and (4) consequently, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Aurora Cannabis Inc. (NYSE: ACB)
Class Period: February 13, 2020 - September 4, 2020
Deadline: December 1, 2020
For more info: www.bgandg.com/acb
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and specifically failed to disclose that: (1) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com